瑞舒伐他汀与辛伐他汀在急性冠脉综合征患者中的应用价值探讨
|
摘要
目的 探索瑞舒伐他汀与辛伐他汀在急性冠脉综合征患者中的应用价值。方法 选取2017年4月—2018年4月期间该院急性冠脉综合征100例患者(实施奇偶数法分组模式),对照组的50例患者进行辛伐他汀治疗,观察组的50例患者进行瑞舒伐他汀治疗。结果 观察组HDL-C(1.01±0.12)mmol/L、LDL-C(2.15±0.36)mmol/L、TG(1.23±0.22)mmol/L、TC(3.45±0.61)mmol/L、MMPI(215.86±15.86)ng/L、hs-CRP(4.62±1.47)mg/L、IMT(1.11±0.08)mm、颈动脉斑块发生率(2.00%)、再发心绞痛(2.00%)、非致死性心肌梗死发生率(0.00%)均优于对照组(t=1.856 4、2.364 4、2.154 2、2.423 6、68.524 1、4.584 1、1.547 5,χ~2=10.326 5、9.8452、7.412 5;P<0.05)。结论 对急性冠脉综合征患者实施瑞舒伐他汀治疗效果更为显著。
Objective To explore the application value of rosuvastatin and simvastatin in patients with acute coronary syndrome. Methods A total of 100 patients with acute coronary syndrome in our hospital from April 2017 to April 2018 were selected. The 50 patients in the control group were treated with simvastatin, and the 50 patients in the observation group were treated with rosuvastatin. Results In the observation group, HDL-C was(1.01±0.12) mmol/L, LDL-C was(2.15±0.36) mmol/L, TG was(1.23±0.22) mmol/L, TC was(3.45±0.61) mmol/L, MMPI was(215.86±15.86) ng/L, hs-CRP was(4.62±1.47) mg/L, IMT was(1.11±0.08) mm, carotid plaque incidence was(2.00%), recurrent angina was(2.00%), and incidence of nonfatal myocardial infarction was(0.00%), which were better than those in the control group(t=1.856 4, 2.364 4, 2.154 2, 2.423 6, 68.524 1, 4.584 1, 1.547 5,χ~2=10.326 5, 9.845 2, 7.412 5; P<0.05). Conclusion The effect of rosuvastatin on acute coronary syndrome is more significant.
Objective To explore the application value of rosuvastatin and simvastatin in patients with acute coronary syndrome. Methods A total of 100 patients with acute coronary syndrome in our hospital from April 2017 to April 2018 were selected. The 50 patients in the control group were treated with simvastatin, and the 50 patients in the observation group were treated with rosuvastatin. Results In the observation group, HDL-C was(1.01±0.12) mmol/L, LDL-C was(2.15±0.36) mmol/L, TG was(1.23±0.22) mmol/L, TC was(3.45±0.61) mmol/L, MMPI was(215.86±15.86) ng/L, hs-CRP was(4.62±1.47) mg/L, IMT was(1.11±0.08) mm, carotid plaque incidence was(2.00%), recurrent angina was(2.00%), and incidence of nonfatal myocardial infarction was(0.00%), which were better than those in the control group(t=1.856 4, 2.364 4, 2.154 2, 2.423 6, 68.524 1, 4.584 1, 1.547 5,χ~2=10.326 5, 9.845 2, 7.412 5; P<0.05). Conclusion The effect of rosuvastatin on acute coronary syndrome is more significant.
引文
[1]王锐,丁良才,盛柯杰,等.瑞舒伐他汀对急性冠脉综合征合并心律失常患者炎性因子的影响[J].江苏大学学报:医学版,2014,24(1):68-71.
[2]冯惠平,贾新未,谢俊敏,等.瑞舒伐他汀对老年急性冠脉综合征患者IL-6、GMP-140、BNP及心功能的影响[J].中国老年学杂志,2015,15(20):5769-5770.
[3]伍珩,韩雅玲,王效增,等.瑞舒伐他汀对急性冠脉综合征合并糖尿病轻、中度肾功能不全患者介入诊治术后心肾功能的影响[J].解放军医学杂志,2014,39(7):546-552.
[4]黄宇理,李妙男,徐玮,等.瑞舒伐他汀对老年急性冠脉综合征患者血浆内皮微粒的影响[J].中国老年学杂志,2015,11(8):2027-2028.
[5]许向东,李宏松.负荷量瑞舒伐他汀对非ST段抬高型急性冠脉综合征早期介入术后患者血管内皮功能的影响[J].中国药房,2016,27(8):1088-1090.
[6]韩冷,倪杰,曹东来,等.瑞舒伐他汀逆转颈动脉斑块与急性冠脉综合征介入治疗近期预后的关系[J].河北医药,2014,14(8):1137-1139.
[7]崔春便.瑞舒伐他汀联合氯吡格雷对急性冠脉综合征患者血管内皮功能及TNFα、IL 1的影响[J].中西医结合心脑血管病杂志,2015,26(3):344-345.
[8]张红心,吴平平,李广平,等.PCI术前强化辛伐他汀治疗对急性冠脉综合征患者术后相关指标的影响[J].中国药房,2017,28(12):1637-1640.
[9]陈万,易星航,赵郑波,等.辛伐他汀对急性冠脉综合征患者血清hs-CRP和妊娠相关血浆蛋白-A水平的影响[J].海南医学院学报,2014,20(7):916-918,922.
[10]王建军.瑞舒伐他汀对急性冠脉综合征患者血清炎性因子、血脂水平及颈动脉斑块的影响[J].广西医学,2014,15(3):338-340.
[2]冯惠平,贾新未,谢俊敏,等.瑞舒伐他汀对老年急性冠脉综合征患者IL-6、GMP-140、BNP及心功能的影响[J].中国老年学杂志,2015,15(20):5769-5770.
[3]伍珩,韩雅玲,王效增,等.瑞舒伐他汀对急性冠脉综合征合并糖尿病轻、中度肾功能不全患者介入诊治术后心肾功能的影响[J].解放军医学杂志,2014,39(7):546-552.
[4]黄宇理,李妙男,徐玮,等.瑞舒伐他汀对老年急性冠脉综合征患者血浆内皮微粒的影响[J].中国老年学杂志,2015,11(8):2027-2028.
[5]许向东,李宏松.负荷量瑞舒伐他汀对非ST段抬高型急性冠脉综合征早期介入术后患者血管内皮功能的影响[J].中国药房,2016,27(8):1088-1090.
[6]韩冷,倪杰,曹东来,等.瑞舒伐他汀逆转颈动脉斑块与急性冠脉综合征介入治疗近期预后的关系[J].河北医药,2014,14(8):1137-1139.
[7]崔春便.瑞舒伐他汀联合氯吡格雷对急性冠脉综合征患者血管内皮功能及TNFα、IL 1的影响[J].中西医结合心脑血管病杂志,2015,26(3):344-345.
[8]张红心,吴平平,李广平,等.PCI术前强化辛伐他汀治疗对急性冠脉综合征患者术后相关指标的影响[J].中国药房,2017,28(12):1637-1640.
[9]陈万,易星航,赵郑波,等.辛伐他汀对急性冠脉综合征患者血清hs-CRP和妊娠相关血浆蛋白-A水平的影响[J].海南医学院学报,2014,20(7):916-918,922.
[10]王建军.瑞舒伐他汀对急性冠脉综合征患者血清炎性因子、血脂水平及颈动脉斑块的影响[J].广西医学,2014,15(3):338-340.